Growth Effects of Tamoxifen and Estradiol on Laryngeal Carcinoma Cell Lines

Kt, Robbins; Tp, Vu; Díaz, Adolfo García; Nm, Varki

doi:10.1001/archotol.1994.01880350067012

Cited by 15 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the first clinical studies have been undertaken [8,23,29]. Similar studies also were conducted on a possible therapy with a testosterone substitute or a block of the 5α-reductase [14].…”

Section: Discussionmentioning

confidence: 99%

“…Although the role of SHR in laryngeal carcinomas is not yet understood, an antiestrogen (Tamoxifen) or an antiandrogen therapy (Flutamide) has already been tested on cell lines as well as in several clinical trials [18,23,29]; these provided adverse results. Therefore, the present study was conducted to evaluate the presence of ER, PR and AR with different methods in the normal mucosa of the larynx and in laryngeal-carcinoma as well as squamous-cell-carcinoma cell lines in order to find out if a biologically relevant amount of receptors is present.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of sex-hormone-receptor expression in laryngeal carcinoma

Hagedorn¹,

Nerlich

2002

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

There are significant differences in how laryngeal cancer affects the two genders, with cases occuring predominantly in males. This has been speculated to result from the different susceptibilities of the tumor cells to steroid sex hormones. Since the sex hormone action is mediated by specific cellular receptors, several previous studies have analyzed the presence of these sex-hormone receptors. However, the data on the receptor status for androgen, estrogen and progesterone receptors in laryngeal carcinomas are controversial. Since some authors have suggested antiandrogen or antiestrogen therapy as an adjuvant treatment for laryngeal carcinoma, we performed a comprehensive study using immunomorphological and biochemical techniques on both in-vivo and in-vitro tumor cells in order to clarify whether major sex-hormone receptors are present or not. We performed an immunohistochemical analysis on 13 patients with laryngeal carcinomas, 8 males and 5 females, using monoclonal antibodies against androgen, estrogen and progesterone receptors. In addition, the presence of estrogen and progesterone receptors was tested biochemically using an enzyme immune assay (EIA). Furthermore, we analyzed immunohistochemically the expression of the hormone receptors in five keratinocyte cell lines originating from laryngeal carcinomas. In all of our tumor samples, as well as in the five tumor cell lines tested, we did not detect any specific immunohistochemical staining for androgen, estrogen and progesterone receptors in the laryngeal carcinoma cells when compared to the positive controls of breast and prostate cancer samples. Similarly, the biochemical analysis did not demonstrate any significant amount of receptor protein in the analyzed cases. In conclusion, the absence of male and female sex-hormone receptors strongly argues against laryngeal carcinomas being sex-hormone-dependent tumors. Therefore, we do not see any rational indication to use a specific antiandrogen or antiestrogen therapy for the adjuvant treatment of laryngeal carcinomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Analysis of sex-hormone-receptor expression in laryngeal carcinoma

Hagedorn¹,

Nerlich

2002

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

show abstract

“…Despite this, laryngeal cancer cells display E 2 responsiveness, as E 2 was found to increase proliferation of laryngeal cancer cells [8], and a non-genomic mechanism was implicated [24]. Furthermore, the effects of E 2 were inhibited by tamoxifen [10].…”

Section: Introductionmentioning

confidence: 99%

17Beta-Estradiol Promotes Aggressive Laryngeal Cancer Through Membrane-Associated Estrogen Receptor-Alpha 36

et al. 2013

View full text Add to dashboard Cite

17β-estradiol (E2) plays a key role in tumorigenesis by enhancing cell survivability and metastasis through its cytoplasmic receptors. Recently, a variant of estrogen receptor alpha, ERα36 has been implicated as a substantial mediator of E2’s proliferative and anti-apoptotic effects through rapid membrane-associated signaling, and cancers previously regarded as hormone-independent due to the absence of traditional receptors, may in fact be susceptible to E2. Despite rising from a secondary sex organ and having a clear gender disposition, laryngeal cancer is not uniformly accepted as hormone-dependent, even in the face of compelling evidence of E2 responsiveness. The aim of this study was to further elucidate the role of E2 in the tumorigenesis of laryngeal cancer, both in vitro and in vivo. ERα36 presence was evaluated in membranes of the laryngeal carcinoma cell line, Hep2, as well as in laryngeal tumor samples. In vitro, ERα36 was found to mediate rapid activation of protein kinase C and phospholipase D by E2, leading to increased proliferation and protection against chemotherapy-induced apoptosis. Furthermore, in response to E2 activation of ERα36, an upregulation of angiogenic and metastatic factors was observed. Clinical analysis of laryngeal tumors revealed a similar association between the amount of ERα36 and VEGF, and indicated a role in lymph node metastasis. These findings present compelling evidence of ERα36-dependent E2 signaling in laryngeal cancer. Thus, targeting ERα36 may reduce the deleterious effects of E2 in laryngeal cancer, ultimately suggesting the importance of anti-estrogen therapy or the production of novel drugs that specifically target ERα36.

show abstract

“…Testosterone has been demonstrated to stimulate the growth of Hep2 laryngeal tumor cells in culture (Zhao et al, 1994) while estrogens and progesterone appear to be unable to affect the proliferation of estrogen receptor (ER)-positive laryngeal carcinoma cells (Zhao et al, 1994;Robbins et al, 1994).…”

mentioning

confidence: 99%

“…Although the growth-inhibitory effects of tamoxifen are considered to be primarily due to competitive antagonism with estrogens at the ER level, Robbins et al (1994) reported that in estrogenunresponsive laryngeal tumor cells, tamoxifen can exhibit a relevant anti-proliferative activity. Moreover, the growth-inhibitory effects of tamoxifen can also be observed in ER-negative cells .…”

mentioning

confidence: 99%